Kiniksa Pharmaceuticals Ltd is a pharmaceutical company based in the United States of America. With a Risk Rating Score of 29.0, the company is classified as having a Medium Risk. Specializing in ESG-focused clinical-stage biopharmaceuticals, Kiniksa Pharmaceuticals is dedicated to developing therapeutic medicines for patients with debilitating diseases. Their product candidates include treatments for conditions such as recurrent pericarditis and giant cell arteritis.